Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study
Condition: Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)
Study Type: Observational
Clinical Trials Identifier NCT 8-digits: NCT04147143
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase:
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Inclusion Criteria:
- Written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject
- Patients with advanced or metastatic renal cell carcinoma, including all subtypes
- Age ≥ 18 years
- Completion of treatment with nivolumab or nivolumab / ipilimumab combination therapy (any line of therapy) directly followed by cabozantinib treatment
Exclusion Criteria:
- Patients who are unable to consent because they do not understand the nature, significance and implications of the observational trial
- Involvement in the planning and / or conduct of the study (applies to both Ipsen staff and/or staff of sponsor and study site)
View trial on ClinicalTrials.gov